Abstract
Background: The immune response to SARS-CoV-2 virus, the cause of COVID-19, is complex. Antibody mediated responses are important for viral clearance but may also drive hyperinflammation in severe COVID-19. We present a case of an individual with a genetic inability to produce antibodies and severe COVID-19, receiving no other specific anti-viral treatment than convalescent COVID-19 plasma, illustrating that hyperinflammation can occur in the absence of a humoral anti-viral response. In addition, the case illustrates that the assessment of SARS-CoV-2 T cell responses can facilitate clinical decision making in patients with COVID-19 and weak or absent humoral immune responses.
Case presentation: A male with X-linked agammaglobulinemia on regular immunoglobulin replacement therapy, hospitalized for 35 days due to severe COVID-19. Systemic inflammatory parameters were highly elevated. After treatment with convalescent COVID-19 plasma he became afebrile and the fatigue diminished. He was discharged on day 42 and nasopharyngeal SARS-CoV-2 PCR eventually was negative on day 49. Evidence of SARS-CoV-2 specific T cells prior to administration of plasma therapy suggested that antibodies were crucial for viral clearance. Regular assessment showed robust and persistent SARS-CoV-2 specific T-cell responses after recovery suggested that prophylactic administration of convalescent COVID-19 plasma was unnecessary.
Conclusion: Assessment of SARS-CoV-2T-cell responses can facilitate the clinical management of COVID-19 patients with humoral immunodeficiencies.
Keywords: COVID-19; Case report; Convalescent plasma therapy; T-cell response; XLA.
【저자키워드】 COVID-19, T-cell Response, Case report, Convalescent plasma therapy, XLA., 【초록키워드】 Treatment, SARS-CoV-2, immune response, therapy, Hospitalized, severe COVID-19, fatigue, antibody, Genetic, SARS-CoV-2 virus, Prophylactic, viral clearance, T cell, nasopharyngeal, response, hyperinflammation, male, Clinical management, plasma, T-cell, convalescent, assessment, humoral immune responses, T cell response, administration, X-linked agammaglobulinemia, SARS-CoV-2 PCR, COVID-19 patient, humoral, systemic, XLA, evidence of, Anti-viral treatment, complex, clinical decision, Specific T-cell response, anti-viral response, afebrile, immunoglobulin replacement therapy, robust, addition, elevated, receiving, facilitate, absence, occur, suggested, discharged, administration of plasma, inflammatory parameter, patients with COVID-19, Regular, 【제목키워드】 Treatment, convalescent plasma, severe COVID-19, humoral, Specific,